Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TACR2 | P21452 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.45 |
| ▸ | CDC25B | P30305 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.44 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.44 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.44 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.43 |
| ▸ | GJB2 | P29033 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12532834 | 1.00 | NT5E (0.48) | NT5ETSHRTACR2PTPN1CDC25B | |
| SCHEMBL12221625 | 0.91 | TSHR (0.58) | TSHRPTPN1LMNAKMT2APOLB | |
| SCHEMBL1775945 | 0.87 | NT5E (0.48) | NT5ETSHRTACR2PTPN1CDC25B | |
| SCHEMBL1775948 | 0.87 | NT5E (0.48) | NT5ETSHRTACR2PTPN1CDC25B | |
| SCHEMBL8992030 | 0.87 | NT5E (0.59) | NT5ETSHRPTPN1CDC25BLMNA | |
| SCHEMBL8992022 | 0.87 | NT5E (0.59) | NT5ETSHRPTPN1CDC25BLMNA | |
| SCHEMBL18607192 | 0.86 | NT5E (0.46) | NT5ETSHRTACR2PTPN1CDC25B | |
| SCHEMBL8992031 | 0.86 | NT5E (0.48) | NT5ETSHRTACR2PTPN1CDC25B | |
| SCHEMBL7174279 | 0.85 | NT5E (0.59) | NT5ETACR2PTPN1CDC25BLMNA | |
| SCHEMBL8222985 | 0.85 | NT5E (0.59) | NT5ETACR2PTPN1CDC25BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956085-B2 | 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-06-07 | — | — | US | disclosed |
| US-20100035961-A1 | Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| WO-2008058628-A1 | NOVEL 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035961-A1 | Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof | BBOX1, CYP2E1, CYP3A4 | NT5E 554/4885TSHR 2116/4885TACR2 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.